{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=exemestane+%28Aromasin%29", "query": { "intervention": "exemestane (Aromasin)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 180, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=exemestane+%28Aromasin%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T22:02:27.913Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03179904", "title": "TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Carcinoma", "HER2-Positive Breast Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Denifanstat", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2017-08-03", "completion_date": "2026-03-13", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-09-26T22:02:27.913Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03179904" }, { "nct_id": "NCT04059484", "title": "Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Metastatic" ], "interventions": [ { "name": "Amcenestrant", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 367, "start_date": "2019-10-22", "completion_date": "2025-01-02", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-09-26T22:02:27.913Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04059484" }, { "nct_id": "NCT04975308", "title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 874, "start_date": "2021-10-04", "completion_date": "2027-08", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-26T22:02:27.913Z", "location_count": 48, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Greenbrae, California + 29 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975308" }, { "nct_id": "NCT05837455", "title": "NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Cancer of the Breast" ], "interventions": [ { "name": "VENTANA MIB-1 Ki67 assay", "type": "DEVICE" }, { "name": "Oncotype DX® Recurrence Score", "type": "DEVICE" }, { "name": "PAM50-based Prosigna breast cancer gene signature assay", "type": "DEVICE" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Combination anthracycline and/or taxane based treatment", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 81, "start_date": "2024-05-30", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-26T22:02:27.913Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05837455" }, { "nct_id": "NCT00066690", "title": "Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Estrogen Receptor Positive Breast Cancer", "Progesterone Receptor Positive Tumor", "Recurrent Breast Carcinoma", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer" ], "interventions": [ { "name": "Exemestane", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Oophorectomy", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Triptorelin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "ETOP IBCSG Partners Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 3066, "start_date": "2003-12-17", "completion_date": "2024-11-06", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-26T22:02:27.913Z", "location_count": 480, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066690" }, { "nct_id": "NCT07483307", "title": "A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2-negative Breast Cancer", "HER2 Negative Breast Carcinoma", "ER+ Breast Cancer", "Lobular Breast Carcinoma" ], "interventions": [ { "name": "Neoadjuvant endocrine therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "FEMALE", "summary": "50 Years and older · Female only" }, "enrollment_count": 176, "start_date": "2026-03-13", "completion_date": "2030-03-13", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-26T22:02:27.913Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07483307" }, { "nct_id": "NCT05645536", "title": "Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "TOL2506", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Letrozole tablets", "type": "DRUG" }, { "name": "Anastrozole Tablets", "type": "DRUG" }, { "name": "Exemestane Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tolmar Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "51 Years", "sex": "ALL", "summary": "18 Years to 51 Years" }, "enrollment_count": 250, "start_date": "2022-12-28", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-26T22:02:27.913Z", "location_count": 17, "location_summary": "Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Columbia", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05645536" }, { "nct_id": "NCT02392611", "title": "Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors and Lymphomas" ], "interventions": [ { "name": "Alobresib", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2015-03-16", "completion_date": "2017-10-11", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-09-26T22:02:27.913Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Fort Wayne, Indiana • Goshen, Indiana + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Goshen", "state": "Indiana" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02392611" }, { "nct_id": "NCT07062965", "title": "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PF-07248144", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-08-05", "completion_date": "2030-11-04", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-26T22:02:27.913Z", "location_count": 102, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07062965" }, { "nct_id": "NCT05635357", "title": "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane/Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 16989, "start_date": "2022-11-01", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2025-07-28", "last_synced_at": "2026-09-26T22:02:27.913Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05635357" } ] }